| CRH |
Report |
Revenue |
IN-LINE |
pred ~$10.79bn vs. cons $10.713bn |
MEDIUM |
| CRH |
Report |
Adjusted EBITDA |
BEAT |
pred ~$2.63bn vs. cons $2.597bn |
MEDIUM |
| CRH |
Report |
Aggregates volume growth |
MISS |
pred ~+1.0% vs. cons +3.0% |
MEDIUM |
| CRH |
Guide |
FY26 Adjusted EBITDA |
UNCHANGED |
guide ~$8.1bn-$8.5bn vs. cons $8.302bn |
MEDIUM |
| CRH |
Guide |
FY26 aggregates volume commentary |
LOWER |
guide ~low-single-digit growth vs. cons +4.7% |
MEDIUM |
| CRH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| CRH |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — flat guide and light volume imply no H2 estimate upgrade |
LOW |